Clinician Outreach and Communication Activity (COCA)

DECEMBER 8, 2022

CDC's website is being modified to comply with President Trump's Executive Orders.

Updates on Multisystem Inflammatory Syndrome in Children (MIS-C): Epidemiology, Case Definition, and COVID-19 Vaccination

AT A GLANCE

During this COCA Call, presenters will review MIS-C epidemiologic and clinical trends, provide a rationale and description of changes in criteria for the new CSTE/CDC MIS-C surveillance case definition compared with the 2020 CDC MIS-C case definition, and discuss information relating to MIS-C and COVID-19 vaccination.

Webinar


Centers for Disease Control and Prevention
Center for Preparedness and Response
Updates on Multisystem Inflammatory Syndrome in Children (MIS-C): Epidemiology, Case Definition, and COVID-19 Vaccination
Clinician Outreach and Communication Activity (COCA) Call
Thursday, December 8, 2022
0:00 / 1:04:41

The fully captioned video and edited transcript will be posted within the next few days.

View slides PDF

Overview

The Council of State and Territorial Epidemiologists (CSTE) and the Centers for Disease Control and Prevention (CDC) have developed a new multisystem inflammatory syndrome in Children (MIS-C) surveillance case definition to help reduce misclassification and complexity. This CDC/CSTE MIS-C surveillance case definition is based on an extensive review of data from 2020–2022. MIS-C is a rare, but severe condition that may occur 2-6 weeks after acute SARS-CoV-2 infection. CDC has been actively involved in MIS-C surveillance, public health investigations, and

development of resources to support the public health and healthcare community. The updated CSTE/CDC MIS-C case definition will become effective on January 1, 2023.

During this COCA Call, presenters will review MIS-C epidemiologic and clinical trends, provide a rationale and description of changes in criteria for the new CSTE/CDC MIS-C surveillance case definition compared with the 2020 CDC MIS-C case definition, and discuss information relating to MIS-C and COVID-19 vaccination.

Presenters

Angela Campbell, MD, MPH, FAAP, FPIDS, FIDSA
Medical Officer
Severe Respiratory Illness and Multisystem Inflammatory Syndrome (SIM) Team Lead
Epidemiology Branch
Coronavirus and Other Respiratory Viruses Division (proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Michael Melgar, MD
Medical Officer
Severe Respiratory Illness and Multisystem Inflammatory Syndrome (SIM) Team
Epidemiology Branch
Coronavirus and Other Respiratory Viruses Division (proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Anna Yousaf, MD
Medical Officer
Severe Respiratory Illness and Multisystem Inflammatory Syndrome (SIM) Team
Epidemiology Branch
Coronavirus and Other Respiratory Viruses Division (proposed)
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention

Call Objectives

COCA Call Objectives

At the conclusion of the session, the participant will be able to accomplish the following:

1. Cite background information on the topic covered during the presentation.
2. Discuss CDC's role in the topic covered during the presentation.
3. Describe the topic's implications for clinicians.
4. Discuss concerns and/or issues related to preparedness for and/or response to urgent public health threats.
5. Promote health improvement, wellness, and disease prevention in cooperation with patients, communities, at-risk populations, and other members of an interprofessional team of healthcare providers.

Activity-Specific Objectives:

At the conclusion of the session, the participant will be able to accomplish the following:

1. Describe epidemiologic and clinical trends in MIS-C over time.
2. List key features of the CSTE/CDC MIS-C surveillance case definition.
3. Discuss information related to MIS-C and COVID-19 vaccination.

Additional Resources

- COVID Data Tracker – MIS-C | CDC
- Multisystem Inflammatory Syndrome (MIS) | CDC
- CSTE 2023 MIS-C case definition position statement PDF
- Clinical Guidance for COVID-19 Vaccination | CDC

- Submitting a Vaccine Adverse Event Reporting System (VAERS) Report and Using VAERS Data | Vaccine Safety Systems | CDC

Continuing Education

To receive continuing education (CE) for **WD4520-120822 – Clinician Outreach and Communication Activity (COCA) Calls/Webinars – Updates on Multisystem Inflammatory Syndrome in Children (MIS-C): Epidemiology, Case Definition, and COVID-19 Vaccination**, please visit CDC TRAIN and search for the course in the Course Catalog using **WD4520-120822**. Follow the steps below by **January 10, 2025.**

1. Register for and complete the course.
2. Pass the post-assessment at 75%.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the **Accreditation Council for Continuing Medical Education (ACCME)**, the **Accreditation Council for Pharmacy Education (ACPE)**, and the **American Nurses Credentialing Center (ANCC)**, to provide continuing education for the healthcare team.

CDC is a Jointly Accredited Provider in Interprofessional Continuing Education.

CME: The Centers for Disease Control and Prevention designates this activity for a maximum of **1** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for **1** AAPA Category 1 CME credits. Approval is valid until **12/13/2023.** PAs should only claim credit commensurate with the extent of their participation

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this **(Knowledge-based)** event for pharmacists to receive **0.1** CEUs in pharmacy education. The Universal Activity Number is **JA4008229-0000-22-127-L04-P** and enduring **JA4008229-0000-22-128-H04-P.**

Once credit is claimed, an unofficial statement of credit is immediately available on CDC TRAIN. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU's for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES®) and/or Master Certified Health Education Specialists (MCHES®) to receive up to **1.0** total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are **1**. Continuing Competency credits available are **1.** CDC provider number **98614.**

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for **1.0** hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program's validity or relevancy to the veterinary profession

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

Fees: No fees are charged for CDC's CE activities.

Target Audience

- Physicians
- Nurses
- Pharmacists
- Veterinarians
- Physician Assistants
- Health Educators
- Other Clinicians

Additional Information

- **Contact Information:** coca@cdc.gov
- **Support/Funding:** Centers for Disease Control and Prevention, Emergency Risk Communication Branch
- **Method of Participation:** You may participate in the educational activity by viewing the program information above.

SOURCES

CONTENT SOURCE: